MERGERS ACQUISITIONSDrug Manufacturers - Specialty & Generic

Bliss GVS Pharma announces an acquisition

Bliss GVS PharmaBLISSGVS

TL;DR

The mandatory open-offer price was Rs 299 per share. Thus, the offer price was substantially above the latest reported book value per share and also above the 60-day VWAP used as a SEBI (SAST) pricing reference.

Per the Detailed Public Statement (DPS) filed for the mandatory open offer, what is the offer price per share, and how does this valuation compare to the company's book value per share and the 60-day volume-weighted average price (VWAP) as mandated by SEBI (SAST) regulations?

The mandatory open-offer price was Rs 299 per share. [1]

Thus, the offer price was substantially above the latest reported book value per share and also above the 60-day VWAP used as a SEBI (SAST) pricing reference. The regulatory comparison is not a standalone fair-value assessment: the Rs 299 price was reported as the applicable offer price under the prescribed takeover-pricing framework, while book value is an accounting measure and the VWAP is a historical market-trading benchmark.

Valuation referenceValueOffer price versus reference
Consolidated book value per share, Q4 FY26Rs 112.75 [2]2.65x, or 165.19% premium — derived
60-day NSE VWAP preceding the public announcementRs 247.55 [3]Rs 51.45 higher, or 20.78% premium — derived

What are the specific disclosures regarding the source of funds for the 47.95% stake acquisition, and does the transaction involve any encumbrance or pledge of the acquired shares by the incoming promoters as detailed in the regulatory filings?

The disclosed funding structure was a Rs 300 Crores term loan plus non-controlling, non-voting equity instruments for the balance. The detailed financing disclosure cited in the transaction coverage does not identify a separate cash-equity contribution or the exact value of the equity instruments. [4]

The completion filing confirms that Mates Visa Consultancy Private Limited and Anupam Rasayan India Limited completed the acquisition of 5,09,84,595 shares, representing 47.95%, with a further 1,669 shares acquired under the open offer; together, they held 5,09,86,264 shares, also representing 47.95%. [5] However, the completion announcement itself does not repeat the funding breakdown. [5]

On pledge or encumbrance: the cited completion filing does not report that the acquired shares were pledged or otherwise encumbered by the incoming promoters. It also does not provide a post-closing promoter-pledge percentage or an explicit “zero encumbrance” confirmation for the acquired block. Accordingly, the supported conclusion is that no encumbrance is reported in the cited completion disclosure, but the available filing extract is insufficient to certify that the shares are legally free of pledge or other encumbrance.

The 0.00% promoter encumbrance shown in the latest shareholding data relates to the pre-acquisition promoter holding and should not be applied to the incoming promoters’ newly acquired shares.

How does the valuation multiple implied by the promoter acquisition price compare to the trailing EV/EBITDA multiples of comparable Indian pharmaceutical companies with significant export exposure to African and emerging markets?

The Rs 299/share acquisition price implies approximately 13.2x FY26 EV/EBITDA for Bliss GVS, materially below the available listed-pharma reference set. It is close to Sanofi India’s derived multiple, but roughly half Supriya Lifescience’s and well below the derived multiples for Innova Captab and Morepen Laboratories.

Transaction valuation

The SPA covered 43.30% of Bliss GVS for Rs 1,369.51 Crores at Rs 299 per share [6]. This implies:

  • Equity value: Rs 1,369.51 Crores / 43.30% = Rs 3,162.84 Crores.
  • FY26 EBITDA: Rs 237.56 Crores [7].
  • FY26 net debt: approximately negative Rs 33.26 Crores, derived from net debt/EBITDA of -0.14x [8] and EBITDA of Rs 237.56 Crores [7].
  • Implied enterprise value: approximately Rs 3,129.58 Crores.
  • Implied EV/EBITDA: 13.17x, or approximately 13.2x.

The net-cash adjustment is modest; the corresponding equity-value/EBITDA multiple is approximately 13.3x.

Comparable valuation reference

Exact September 2026 TTM EV/EBITDA multiples are not directly reported on a like-for-like basis. The comparison below therefore uses a common FY26 reported denominator. The derived proxy is:

`EV/EBITDA = (FY26 P/E × FY26 PAT / FY26 EBITDA) + FY26 net debt/EBITDA`

Interpretation

  • Against the strongest geographic comparator, Supriya Lifescience, Bliss was acquired at roughly a 49% lower EV/EBITDA multiple: 13.2x versus 25.8x.
  • Against Sanofi India, the discount is limited: approximately 13.2x versus 14.3x. However, Sanofi is not a clean Africa/emerging-market analogue based on the disclosures cited.
  • Against Innova Captab and Morepen, the discount is much wider, at roughly 17.2 turns and 33.0 turns respectively.
  • Bliss’s discount is not solely a function of export exposure. ICRA identifies substantial Africa concentration, elevated receivable and customer-concentration risk, past receivable write-offs, currency exposure and regulatory risk; Africa was estimated at 65–75% of revenue and exports exceeded 90% [27]. Those risks can reasonably explain part of the lower transaction multiple.
  • The transaction multiple should not be confused with the subsequent listed-market valuation: the latest completed trading session on 28 September 2026 closed at Rs 737.65, well above the Rs 299 acquisition price. The negotiated SPA multiple therefore represents the control transaction valuation, not the current public-market multiple.
CompanyDerived FY26 EV/EBITDABasis and export-market relevance
Bliss GVS — acquisition price13.2xSPA implied EV divided by FY26 consolidated EBITDA; deal price [6], EBITDA [7], net debt/EBITDA [8]
Innova Captab30.4xConsolidated FY26; P/E 51.6x [9], PAT Rs 140.92 Crores [10], EBITDA Rs 250.33 Crores [11], net debt/EBITDA 1.36x [12]. African/emerging-market mix not quantified in the cited material
Sanofi India14.3xStandalone FY26; P/E 23.1x [13], PAT Rs 309.80 Crores [14], EBITDA Rs 483.00 Crores [15], net debt/EBITDA -0.54x [16]. Broad valuation reference, not a verified Africa-focused comparable
Symbiotec PharmalabN/DNo comparable market-based EV/EBITDA inputs or qualifying export-geography disclosure
Supriya Lifescience25.8xStandalone FY26; P/E 37.9x [17], PAT Rs 209.12 Crores [18], EBITDA Rs 305.53 Crores [19], net debt/EBITDA -0.12x [20]. Export contribution was approximately 82%; FY26 geography was Europe 40%, Asia 33% and LATAM 20% [21]
Morepen Laboratories46.2xConsolidated FY26; P/E 69.8x [22], PAT Rs 94.87 Crores [23], EBITDA Rs 146.96 Crores [24], net debt/EBITDA 1.11x [25]. Q1 FY27 export revenue grew 111% and API exports 42%, but the African/emerging-market mix was not quantified [26]

Sources

  1. [1]Anupam Rasayan launches open offer to acquire 26% stake in Bliss GVS Pharma at ₹299 per share - CNBC TV18 — CNBC TV18, 2026-07-21T00:00:00
  2. [2]Book Value Per Share
  3. [3]Anupam Rasayan revises Bliss GVS open offer timeline, IDC recommends tender — Scanx, 2026-07-27T00:00:00
  4. [4]Anupam Rasayan to Buy 74.2% Bliss GVS at ₹299 in 2026 — Multibagg, 2026-09-28T16:06:13.113548
  5. [5]Bliss GVS Pharma: Change in Control, Promoter Acquisition of 47.95% Stake, and Board Reconstitution — 2026-09-28T20:32:31.120000, p.1
  6. [6]Bliss GVS Pharma jumps 20% on Anupam stake deal 2026 — Multibagg, 2026-09-28T16:09:21.499750
  7. [7]TTM EBITDA
  8. [8]TTM Net Debt to EBITDA
  9. [9]P/E Ratio
  10. [10]PAT
  11. [11]EBITDA
  12. [12]Net Debt to EBITDA
  13. [13]P/E Ratio
  14. [14]PAT
  15. [15]EBITDA
  16. [16]Net Debt to EBITDA
  17. [17]P/E Ratio
  18. [18]PAT
  19. [19]EBITDA
  20. [20]Net Debt to EBITDA
  21. [21]Dear Sir/Madam, - supriyalifescience.com — Supriyalifescience, 2026-05-28T00:00:00
  22. [22]P/E Ratio
  23. [23]PAT
  24. [24]EBITDA
  25. [25]Net Debt to EBITDA
  26. [26]Morepen Labs revenue rises 34% to Rs. 575 crore as CDMO business enters commercial phase — Indianpharmapost, 2026-08-04T00:00:00
  27. [27]Bliss GVS Pharma Limited — Icra, 2026-04-08T00:00:00

Keep digging

Per the Detailed Public Statement (DPS) filed for the mandatory open offer, what is the offer price per share, and how does this valuation compare to the company's book value per share and the 60-day volume-weighted average price (VWAP) as mandated by SEBI (SAST) regulations?

Ask Copilot
Logo

Unlock financial AI for your firm

Log in